This week delivered a useful reminder that health and wealth rarely move on separate tracks. Interest rates, energy prices, public-health concerns, and advances in mental-health treatment can all affect the same household… sometimes simultaneously.
The larger lesson is not to predict every headline. It is to build enough margin into our health, finances, and daily routines that one difficult week does not knock us completely off course.
The Federal Reserve Raises Rates Again
The biggest financial story came from the Federal Reserve. On September 16, the Fed raised its target range for the federal funds rate by a quarter percentage point, bringing it to 3.75%–4.00%. The vote was unanimous.
For consumers, another rate increase can translate into higher borrowing costs on credit cards, variable-rate debt, auto loans, and eventually some mortgages. Savers may benefit if banks and money-market funds pass along higher yields, but that benefit can be offset when household expenses rise at the same time.
Investors should resist making an all-or-nothing move based on one Fed meeting. Higher rates can pressure richly valued growth stocks, real estate, and other rate-sensitive assets. However, they can also create opportunities in cash-equivalent investments, short-term Treasuries, and financially strong companies that generate dependable cash flow.
My approach remains simple: stay diversified, keep some cash available, dollar-cost average into high-conviction positions, and avoid chasing whatever moved the most this week. Volatility is uncomfortable, but it can also reward patience and preparation.
Energy Costs Are Becoming a Household Issue Again
Rising gasoline and diesel prices are more than a transportation story. Diesel powers the trucks, equipment, and supply chains that move much of what Americans buy. When those costs increase, businesses often pass at least part of the expense to consumers.
That means higher energy prices can appear in grocery bills, delivery fees, airfare, household goods, and corporate profit margins. They can also complicate the Fed’s inflation fight because energy touches nearly every part of the economy.
For households, this is a good week to review spending rather than panic. Small adjustments combining errands, checking insurance and subscription costs, using fuel rewards wisely, and directing extra cash toward high-interest debt can help absorb rising prices without abandoning long-term investing goals.
Investors should watch companies with heavy transportation, manufacturing, or distribution costs. Revenue growth may look healthy while margins quietly weaken. In this environment, balance-sheet strength and pricing power matter.
Mental-Health Treatment Continues to Evolve
On September 14, the FDA held a public hearing on the potential future therapeutic use of psychedelic drug products in supervised and supportive settings. The agency gathered perspectives on possible benefits, risks, clinical standards, patient protections, and the evidence that would be required.
This does not mean psychedelic treatments have received broad approval. It does show that federal regulators are seriously examining how emerging therapies might fit into a safe, evidence-based medical framework.
That matters to me personally. After completing TMS and reaching remission from depression, I understand how meaningful it can be when a treatment finally helps after a long struggle.
Innovation deserves hope but also discipline. New mental-health therapies require careful research, qualified medical supervision, honest discussions about risk, and strong protections for vulnerable patients.
The encouraging trend is that mental health is increasingly being treated like health: something worthy of scientific investment, open conversation, and individualized care.
Public-Health Awareness: Rare Does Not Mean Ignorable
Rabies concerns also received attention this week following several unusual animal-exposure incidents. Human rabies remains rare in the United States, but it is almost always fatal after symptoms appear. The good news is that prompt wound cleaning, medical evaluation, and post-exposure vaccination can prevent the disease when treatment begins in time.
The practical takeaway is straightforward: never dismiss a bite, scratch, or possible saliva exposure involving a bat or an unfamiliar wild or domestic animal. Wash the area thoroughly and contact a healthcare professional or local health department promptly. Pet owners should also keep their animals’ vaccinations current.
Preparedness is not fear. It is knowing what deserves immediate action.
One Step Forward
This week’s health and wealth stories point toward the same principle: protect your margin.
Financial margin means maintaining emergency savings, controlling expensive debt, diversifying investments, and leaving room to take advantage of opportunities.
Health margin means keeping appointments, following treatment plans, remaining active, sleeping as well as possible, and responding promptly when something feels wrong.
My one step forward this week is to review one area of vulnerability instead of trying to fix everything at once. That could mean checking the interest rate on a credit card, adding a little to an emergency fund, scheduling a delayed medical appointment, or simply getting outside for a daily walk.
Progress is rarely one giant decision. More often, it is a series of small choices that make us harder to knock down.
Disclaimer: This article is for educational and informational purposes only. It is not medical, investment, tax, or financial advice. Consult qualified professionals regarding your individual circumstances.
About the Author:
David Dandaneau is a client relations analyst that covers the insurance and financial services industry. He is known for his insightful analysis and comprehensive coverage of market trends and regulatory developments.
On September 16, 2026, I completed my 36th and final TMS session.
After weeks of treatments, early-morning walks, difficult days, small victories and honest reflection, I reached the finish line. More importantly, I reached it feeling like my depression had finally entered remission.
I use the word “remission” carefully. Mental health recovery does not come with guarantees, and I cannot predict what the months ahead will bring. But today, I feel better. I am thinking more clearly, laughing again and returning to parts of life that depression had slowly pushed into the background.
That deserves to be celebrated.
But finishing TMS also taught me something important: completing treatment is not the end of the journey. It is the beginning of learning how to live again with intention.
A sunlit bedside table gathers everyday essentials for sleep, wellness, and a fresh start.
TMS Did Not Make Life Perfect
My TMS journey took place during a complicated season of life.
I lost Dolly, my dog of 17 years. I watched people I love struggle with their own emotions. I dealt with health problems, disrupted sleep and the uncertainty surrounding my return to work. Some days I felt strong. Other days, simply completing my treatment session was the victory.
TMS did not remove grief, stress or responsibility from my life. What it appeared to do was help create enough space for me to face those things without being completely overwhelmed by depression.
That distinction matters.
Recovery does not mean that nothing hurts anymore. It means the pain no longer controls every thought, decision and moment of the day. It means being able to experience a difficult event without automatically losing yourself inside it.
For me, progress began showing up in ordinary moments.
I started walking again. I made breakfast. I worked out. I prepared lunch. I spent time with my family. I took a trip to Las Vegas to celebrate my son Aidan’s 21st birthday and walked nearly 10 miles on some days.
None of those things sound extraordinary on their own. But when you have experienced depression, returning to ordinary life can feel extraordinary.
Returning to Work Without Trying to Prove Everything
Just two days after completing TMS, I prepared to return to work following an extended medical leave.
Part of me wanted to come back at full speed and prove that I was completely healed. But recovery is not something we prove through exhaustion. I do not need to make up for every difficult day by pushing myself beyond reasonable limits.
The better goal is consistency.
That means showing up, doing the work in front of me and allowing myself time to adjust. It means recognizing that returning to work is another step forward not a test of whether treatment “worked.”
This lesson applies beyond mental health. Whenever we recover from an illness, loss, financial setback or major disruption, there can be pressure to reclaim everything immediately. But sustainable progress usually happens through structure, patience and small decisions repeated over time.
My Routine Is Part of My Recovery
During treatment, I learned how much I benefit from structure. When I have too much unplanned time, my thoughts can begin racing. When my day has purpose, movement and manageable goals, I generally function better.
My post-TMS routine does not need to be complicated. It can begin with a few basic commitments:
Maintain a consistent sleep and wake schedule.
Use my CPAP and continue paying attention to sleep quality.
Walk or exercise regularly without treating every workout like a test.
Eat regular meals and stay hydrated.
Take medications only as prescribed and discuss concerns with my healthcare providers.
Keep follow-up appointments even when I am feeling well.
Pay attention to changes in mood, sleep, energy, impulsivity or anxiety.
Stay connected with my wife, family and trusted friends.
Continue writing honestly about the journey.
The National Institute of Mental Health recommends maintaining routines for sleep, meals and physical activity while staying connected to trusted people. For people living with bipolar disorder, it also emphasizes ongoing treatment, regular appointments and tracking changes in mood.
These habits are not replacements for professional care. They are ways to support the care I am already receiving.
Remission Is Not Permission to Stop Paying Attention
Feeling better can create its own temptation: the belief that continued treatment, medication management or follow-up care is no longer necessary.
That is a conversation for a qualified medical professional, not a decision to make alone.
Because I live with bipolar disorder, depression, ADHD, PTSD and anxiety, I know that changes in sleep, energy or behavior deserve attention. Feeling productive and energetic may be a sign of improvement, but dramatic changes such as needing much less sleep, racing thoughts, unusual irritability or impulsive decisions should not simply be dismissed as having a few great days.
The goal is not to live in fear of another episode. The goal is to know myself well enough to recognize meaningful changes early and ask for help when I need it.
Tracking a few daily indicators may help:
Hours and quality of sleep
Overall mood
Energy level
Anxiety
Exercise or movement
Medication consistency
Any unusual changes noticed by family
This is not about obsessing over every emotion. Everyone has good and bad days. It is about looking for patterns.
A sunlit bedside table gathers everyday essentials for sleep, wellness, and a fresh start.
One Step Forward
My “One Step Forward” campaign on Instagram began as a reminder that progress does not have to be dramatic to matter.
That message feels even more meaningful now.
Finishing TMS was a major step. Returning to work was another. But the steps that sustain recovery may be much smaller: taking a walk, getting enough sleep, eating breakfast, attending an appointment or telling someone when I am struggling.
I do not know exactly what the future holds. None of us do. What I know is that I feel hopeful again and hope is something I refuse to take for granted.
My depression may be in remission, but my commitment to my health continues.
Treatment helped me reach this point. Routine, support, follow-up care and self-awareness can help me protect the progress I have made.
Health is not separate from wealth. It is the foundation that allows us to work, create, invest, connect and enjoy the life we are trying to build.
Today, I am not promising perfection. I am choosing consistency.
One walk. One workday. One healthy decision. One honest conversation.
One step forward.
Author’s note: This article reflects my personal experience and is intended for general education and encouragement. TMS outcomes and mental health needs vary by individual. It is not medical advice and should not be used to start, stop or change treatment or medication. Speak with a qualified healthcare professional about your personal care. If you are in crisis or experiencing thoughts of self-harm, call or text 988 in the United States.
Cerebras Systems Inc. (NASDAQ: CBRS) has emerged as one of the more intriguing and volatile public companies attempting to reshape how artificial intelligence models are trained and, increasingly, how quickly they can perform inference.
Cerebras went public in May 2026 in one of the year’s most closely watched technology IPOs. Shares were priced at $185, and the completed offering raised approximately $6.38 billion in gross proceeds.
Four months later, the investment thesis is becoming clearer: Cerebras has extraordinary growth opportunities, but investors are paying a substantial valuation for that opportunity.
The artificial-intelligence infrastructure race is no longer simply about NVIDIA and GPUs.
Rows of illuminated servers and overhead cabling power this expansive modern data center.
What Makes Cerebras Different?
Cerebras attacks the AI computing problem differently from traditional GPU manufacturers.
Its core technological innovation is the Wafer Scale Engine (WSE). Rather than cutting a semiconductor wafer into numerous individual chips and connecting those processors together, Cerebras essentially turns an enormous portion of the wafer itself into one processor.
The objective is straightforward: eliminate many of the communication bottlenecks associated with moving information between individual chips.
Cerebras has increasingly focused this technology on high-speed AI inference the process of actually running trained AI models and generating answers for users and applications.
That distinction is important.
As AI moves from experimentation toward widespread commercial deployment, inference could become an enormous recurring infrastructure market. Every AI search, coding agent, autonomous workflow, enterprise chatbot and reasoning system consumes inference compute.
Cerebras wants to supply a meaningful portion of that compute.
Revenue Growth Is Accelerating
The company’s financial trajectory illustrates why investors are paying attention.
Cerebras generated approximately $290.3 million of revenue in 2024, increasing to roughly $510 million in 2025, representing 76% year-over-year growth.
Growth accelerated further during 2026.
First-quarter core revenue reached $191.3 million, up 92% year over year, including $111.6 million of hardware revenue and $79.8 million from cloud and other services.
Then came Q2.
Cerebras reported approximately $210 million of core revenue, while its core cloud business grew 287% year over year. The company also reported that it had secured approximately 600 megawatts of data-center capacity and planned to expand manufacturing capacity by more than tenfold during 2026.
Management subsequently increased its full-year outlook.
Cerebras now expects 2026 core revenue of approximately $880 million to $890 million, with core gross margins between 41% and 43% and core operating margins between negative 19% and negative 17%.
At the midpoint, $885 million would represent roughly 74% growth over 2025 revenue.
That is serious growth.
But it comes with an important caveat: Cerebras is still spending heavily to build the infrastructure necessary to capture that opportunity.
The $20+ Billion OpenAI Opportunity
Potentially the biggest component of the Cerebras growth story is its relationship with OpenAI.
Cerebras announced a multi-year agreement involving 750 MW of capacity valued at more than $20 billion. The company has also announced a multi-year partnership with Amazon to bring Cerebras inference technology to AWS.
These relationships potentially accomplish something extremely important for Cerebras: validation.
Competing against entrenched semiconductor and cloud-computing ecosystems requires more than superior benchmark performance. Customers need confidence that Cerebras can deploy its technology reliably and at enormous scale.
Large AI customers and cloud partners can help establish that credibility.
Cerebras has additionally disclosed customers or relationships involving companies such as Cognition, Lovable, Block, Figma, AlphaSense, GSK and CrowdStrike.
The company is therefore beginning to look less like an experimental AI-chip developer and more like an emerging AI infrastructure platform.
The CS-4 Could Be the Next Catalyst
Cerebras unveiled its next-generation CS-4 system in August, claiming performance of up to 30 times faster than GPU-based alternatives in certain workloads. The company is simultaneously expanding its global infrastructure footprint, including a recently announced 165 MW AI data center in Finland.
Those developments are worth watching closely.
AI infrastructure ultimately becomes an economics problem. Performance matters, but customers also care about cost per token, power consumption, latency, reliability and scalability.
If Cerebras can consistently demonstrate materially better inference economics—not merely impressive benchmark speeds—it could capture a meaningful piece of the rapidly expanding inference market.
The Financial Risk Investors Shouldn’t Ignore
The bull case is compelling, but CBRS isn’t a low-risk semiconductor investment.
First, profitability remains a work in progress.
Although Cerebras reported GAAP net income of $237.8 million during 2025, its filing shows a non-GAAP net loss of approximately $75.7 million, and the company explicitly warns investors that it has a history of generating losses.
Management’s 2026 guidance still calls for a substantially negative core operating margin.
Second, gross margins deserve close attention.
Q1 core gross margin was an impressive 47%, but Cerebras has been investing aggressively in cloud infrastructure and data-center capacity. The company currently expects full-year core gross margin of approximately 41%-43%.
Third, customer concentration has historically been significant. Large contracts can produce extraordinary revenue growth, but dependence on a relatively small number of enormous customers can also create significant volatility if deployments are delayed, renegotiated or canceled.
Finally, there is competition.
Cerebras isn’t operating in an empty market. NVIDIA dominates AI accelerators, while AMD, hyperscale cloud providers and custom silicon developers are all pursuing the same enormous AI-compute opportunity.
Cerebras doesn’t necessarily need to defeat NVIDIA to succeed.
It does, however, need to prove that wafer-scale computing occupies a sufficiently valuable niche within the broader AI infrastructure ecosystem.
Valuation: This Is Where Things Get Interesting
CBRS currently trades around $184, putting the company near its original $185 IPO price after experiencing substantial volatility since its May debut.
That matters psychologically, but the more important question is valuation.
With management forecasting approximately $885 million of 2026 core revenue, investors are already assigning Cerebras a substantial premium based on expectations of continued hypergrowth.
In other words, today’s CBRS valuation isn’t primarily based on what Cerebras earns today.
Investors are buying expectations for what the company could become several years from now.
That makes execution extremely important.
A company growing revenue 60%-80% annually can grow into a seemingly expensive valuation remarkably quickly. But if growth falls toward 20%-30% while profitability remains elusive, valuation compression can be equally dramatic.
My 12-Month CBRS Scenario Analysis
Forecasting a recently public, high-growth AI semiconductor company to a single price would create a false sense of precision. A scenario framework is more useful.
Bear Case: $120-$150
This scenario could develop if revenue growth decelerates, cloud margins deteriorate, major capacity deployments are delayed, customer concentration becomes problematic or investors broadly reduce the multiples they are willing to pay for AI infrastructure companies.
From approximately $184 today, that represents meaningful downside.
Base Case: $240-$300
This scenario assumes Cerebras continues producing strong revenue growth, approaches or exceeds its current guidance, demonstrates improving operating leverage and successfully converts its enormous infrastructure commitments into recurring cloud revenue.
Interestingly, current Wall Street research sits in roughly this neighborhood. Needham reiterated a $300 price target following the company’s first-quarter results.
Aggregated analyst data recently showed an average target around $292, although analyst targets should always be viewed as estimates rather than predictions.
Bull Case: $350-$425
For Cerebras to reach this range, I would want to see several things happen simultaneously: revenue expectations moving materially above $1 billion, continued triple-digit or near-triple-digit cloud growth, successful OpenAI capacity deployments, evidence of attractive CS-4 economics, improving gross margins and a credible path toward operating profitability.
A sustained AI infrastructure spending cycle could provide an additional tailwind.
This is the highest-risk scenario because it requires both strong fundamental execution and investors continuing to award CBRS a premium valuation.
What I’m Watching Next
For investors holding CBRS, I believe five metrics deserve particular attention over the coming quarters:
Cloud revenue growth: arguably the most important long-term metric because recurring inference revenue could eventually be more valuable than one-time hardware sales.
Gross margin: rapid revenue growth means much less if infrastructure costs consume the economics.
OpenAI deployment progress: successful conversion of the announced $20+ billion relationship into actual revenue could fundamentally alter Cerebras’ financial profile.
Operating losses: Cerebras needs to demonstrate that revenue can eventually grow considerably faster than operating expenses.
Customer diversification: additional enterprise and hyperscale customers would reduce dependence on a handful of massive relationships.
The Bigger Picture
Cerebras represents a particularly interesting kind of AI investment.
This isn’t simply another company adding artificial intelligence to an existing product.
Cerebras is building the physical infrastructure required to run AI itself.
The company increased revenue from just $24.6 million in 2022 to $510 million in 2025, and management now expects approximately $880-$890 million in core revenue during 2026.
Meanwhile, cloud revenue is growing at nearly 300%, manufacturing capacity is expanding dramatically, hundreds of megawatts of data-center capacity are under contract, and Cerebras is developing relationships with some of the most important companies in artificial intelligence.
That’s the opportunity.
The risk is that investors already recognize much of it.
At approximately $184 per share, CBRS remains a high-growth, high-expectation investment where quarterly execution can produce enormous price swings, as demonstrated when shares dropped sharply following the company’s August earnings release despite management raising its annual outlook.
My working 12-month framework therefore puts $240-$300 as a reasonable base-case range, with approximately $120-$150 representing a bearish execution/valuation scenario and $350-$425 representing a strong-execution bull scenario.
Those ranges aren’t price targets or guarantees. They are a framework for measuring future results against the expectations embedded in the stock.
For investors already holding Cerebras, the central question isn’t simply whether artificial intelligence will continue growing.
It almost certainly will.
The more important question is whether Cerebras can convert its technological advantage, enormous customer agreements and rapidly expanding infrastructure footprint into durable revenue growth and ultimately durable profits.
If it can, CBRS could become one of the more important publicly traded AI infrastructure companies to emerge from this generation of the technology boom.
Disclosure: I currently hold a position in Cerebras Systems (NASDAQ: CBRS). This article reflects personal research and analysis and is provided for informational purposes only. It is not financial advice or a recommendation to buy or sell any security. Investing involves risk, including the possible loss of principal.
Retirement doesn’t necessarily mean the end of a paycheck. For millions of Americans, working part-time, consulting, starting a small business or even returning to a full-time career can provide additional income, social connection and a sense of purpose.
But there is an important financial catch: earning money after claiming retirement benefits can affect more than just your bank account.
Depending on your age and income, working in retirement can influence your Social Security benefits, federal taxes and even what you pay for Medicare.
A person reviews retirement plans and calculates finances at a warm, sunlit desk.
Working While Collecting Social Security
One of the biggest misconceptions about retirement is that you cannot work while receiving Social Security. You can.
However, if you claim Social Security before reaching full retirement age, your earnings may trigger the Social Security retirement earnings test.
For 2026, if you are under full retirement age for the entire year, Social Security will deduct $1 from benefits for every $2 earned above $24,480.
If you reach full retirement age during 2026, the limit increases to $65,160, with $1 withheld for every $3 earned above that amount until the month you reach full retirement age. Once you reach full retirement age, there is no earnings limit.
Importantly, money withheld under the earnings test isn’t necessarily gone forever. Social Security recalculates benefits at full retirement age to account for months when benefits were withheld because of excess earnings.
A simple example
Suppose a 64-year-old begins receiving Social Security and earns $40,000 from a job in 2026.
The first $24,480 is below the earnings limit.
That leaves $15,520 above the limit. Social Security would withhold approximately $7,760 in benefits under the $1-for-$2 rule.
That doesn’t necessarily mean working is a bad financial decision. The additional wages could still leave the individual substantially better off overall but the calculation needs to include the reduced current benefit.
Your Paycheck Can Also Increase Your Tax Bill
Retirement income isn’t automatically tax-free.
Wages, self-employment income, pensions, IRA withdrawals and other taxable income can increase your overall tax liability. In addition, Social Security benefits can become taxable when your combined income reaches certain levels.
The IRS generally looks at one-half of your Social Security benefits plus other income, including tax-exempt interest, when determining whether benefits may be taxable.
That means a retiree who takes a part-time job may unintentionally push more of their Social Security benefits into taxable income.
And don’t forget payroll taxes. Even when you’re already receiving Social Security, wages can still be subject to federal income-tax withholding, Social Security tax and Medicare tax.
Medicare Could Become More Expensive, Too
Here’s the part many retirees don’t see coming.
Higher income can affect Medicare premiums through something known as IRMAA the Income-Related Monthly Adjustment Amount.
IRMAA can increase what you pay for Medicare Part B and Part D when your income exceeds specified thresholds. For 2026, the standard Part B premium is $202.90 per month, although higher-income beneficiaries can pay substantially more.
For 2026, the initial IRMAA threshold is based on modified adjusted gross income above $109,000 for individuals or $218,000 for married couples filing jointly. Medicare generally uses tax information from two years earlier when determining these income-related premiums.
That creates an important planning issue.
The extra income you earn today could potentially affect your Medicare premiums two years from now.
Don’t Forget the Social Security Wage Tax
Working in retirement can also mean continuing to pay into Social Security.
In 2026, Social Security payroll taxes apply to earnings up to $184,500. Medicare taxes, however, continue to apply to earnings without that Social Security wage cap.
For someone returning to a high-paying career after retirement, that distinction can become significant.
Working Longer Can Have an Upside
The financial consequences aren’t all negative.
Continuing to work can provide several advantages:
Additional cash flow without immediately drawing as heavily from retirement savings.
More years of Social Security-covered earnings, which can potentially increase a benefit calculation.
Delayed withdrawals from retirement accounts, allowing investments more time to potentially grow.
Employer health coverage, if available and appropriate.
Social and psychological benefits from staying active and engaged.
The ability to potentially delay Social Security and receive a larger monthly benefit later. Social Security says retirement benefits can generally be claimed between ages 62 and 70, with monthly benefits increasing the longer you wait to claim, up to age 70.
For some retirees, working isn’t simply about making ends meet. It can be a deliberate part of a broader retirement strategy.
The Bottom Line: Don’t Look at Salary in Isolation
A $30,000 part-time job isn’t necessarily a $30,000 improvement to your retirement finances.
The real question is:
How much of that additional income will you actually keep after considering Social Security, federal and state taxes, Medicare premiums and other retirement-income sources?
Before accepting a job or starting a business in retirement, consider running several scenarios:
Work less → work more → delay Social Security → claim Social Security now.
Compare the after-tax income and long-term effects of each option rather than focusing solely on the paycheck.
And remember that everyone’s situation is different. Filing status, age, Social Security claiming date, retirement-account withdrawals, investment income and Medicare status can materially change the outcome.
A quiet garden path leads toward a reflective river beneath a warm sunset sky.
Retirement Isn’t a Finish Line- It’s a Financial Transition
For today’s retirees, the traditional idea of completely stopping work at 65 is increasingly becoming just one option among many.
Working during retirement can be financially rewarding, but it requires coordination between Social Security, taxation, retirement savings and Medicare.
The smartest approach isn’t necessarily to avoid earning additional income.
It’s to understand what that income does to the rest of your financial picture before you earn it.
This article is for educational purposes only and is not individualized tax, legal, Social Security or financial advice. Consider consulting a qualified financial professional, tax professional or Social Security representative before making retirement-income decisions.
Sources: Social Security Administration, Medicare.gov and Internal Revenue Service.
David Dandaneau is a client relations analyst that covers the insurance and financial services industry. He is known for his insightful analysis and comprehensive coverage of market trends and regulatory developments.
The weight-loss revolution is no longer just about losing weight. It is becoming a major financial issue for employers, insurers and American families.
GLP-1 medications have rapidly transformed the treatment of obesity and related health conditions. Drugs such as Wegovy and Mounjaro have moved from being relatively specialized treatments to becoming some of the most closely watched medications in the healthcare industry.
Now, the financial impact is becoming impossible for employers to ignore.
Recent healthcare industry reporting shows that GLP-1 medications are forcing employers to reconsider how they structure and finance employee healthcare benefits. The growing demand for these medications has created a difficult balancing act: employers want to provide effective treatment for obesity and chronic disease, but they also have to manage rapidly increasing pharmacy costs.
A stethoscope, glucose meter, calculator, and fresh vegetables highlight everyday diabetes care.
Why GLP-1 medications matter
The appeal of GLP-1 medications goes far beyond the number on the bathroom scale.
Obesity is associated with numerous health conditions, including cardiovascular disease, type 2 diabetes and other chronic illnesses. As a result, employers and insurers increasingly have to consider whether paying for obesity treatment today could potentially reduce healthcare costs associated with complications later.
That creates an important question:
Is a more expensive medication today actually an investment in lower healthcare costs tomorrow?
The answer isn’t simple.
GLP-1 therapy can be expensive, and patients may require long-term treatment. That means employers could face substantial recurring pharmacy expenses if large numbers of employees gain coverage.
At the same time, preventing or improving chronic conditions could potentially generate savings elsewhere in the healthcare system.
This is where the health and wealth sides of the equation collide.
The employer healthcare dilemma
For decades, employers have struggled with rising healthcare premiums, hospital costs, specialty drugs and chronic disease management.
GLP-1 medications add another layer to the problem.
Companies must determine whether to:
Cover GLP-1 medications broadly.
Require prior authorization or other utilization-management strategies.
Limit coverage to specific medical indications.
Pair medication coverage with nutrition, exercise and behavioral-health programs.
Exclude coverage entirely.
None of these choices is easy.
Restricting access can reduce short-term spending, but employers may worry about employee satisfaction and long-term health outcomes. Providing unrestricted access may improve treatment availability but create significant pharmaceutical expenses.
The challenge is finding a sustainable middle ground.
Healthcare is moving toward a broader definition of value
One of the most interesting developments is that GLP-1 treatment is increasingly being viewed as part of a broader healthcare strategy rather than simply a weight-loss benefit.
The federal government’s CMS BALANCE model, announced in August, is designed to expand access to GLP-1 medications for eligible Medicare and Medicaid beneficiaries while combining medication with lifestyle interventions such as diet and physical activity.
That approach highlights an important principle:
Medication may be most effective when it is part of a larger health strategy.
Instead of viewing obesity treatment as simply paying for a prescription, healthcare organizations are increasingly examining the potential benefits of combining medication with nutrition, physical activity and behavioral support.
That could ultimately change how employers design wellness programs.
The financial opportunity & risk
From an investment perspective, GLP-1 medications have created an enormous pharmaceutical market.
Companies developing obesity treatments are competing to improve effectiveness, reduce side effects, extend dosing intervals and develop alternatives to injections.
The next phase could be particularly important: oral medications and next-generation treatments could make obesity therapy more convenient and potentially expand the market even further.
But investors should remember that a booming healthcare market does not automatically mean every company involved will be a winner.
Drug pricing, insurance coverage, regulatory decisions, competition and patient retention can dramatically affect pharmaceutical companies’ revenue and profitability.
There is also a growing concern about consumers obtaining weight-loss medications through unregulated channels.
A Reuters report published August 31 highlighted the growing black market for GLP-1 drugs in Brazil, where demand for lower-cost alternatives has contributed to the circulation of smuggled and unregulated products. Health officials have linked these products to serious complications and deaths.
That serves as an important reminder:
When demand for healthcare becomes enormous, the economics can create both innovation and unintended consequences.
What this means for consumers
For individuals considering GLP-1 therapy, the conversation shouldn’t begin and end with weight loss.
Patients should discuss the potential benefits, risks, costs and long-term treatment strategy with a qualified healthcare professional.
The cheapest medication isn’t necessarily the best option, and the newest medication isn’t automatically the best option either.
The real value comes from finding a treatment strategy that improves health while remaining financially sustainable.
The Health to Wealth takeaway
The GLP-1 revolution represents something much bigger than a pharmaceutical trend.
It is a case study in how health and wealth are interconnected.
If these medications help millions of people improve their health, the potential benefits could extend beyond individual patients to employers, insurers and the broader healthcare system.
But somebody has to pay for that treatment.
That is why the next chapter of the GLP-1 story may be less about whether these medications work and more about who pays, how much they pay, and whether the long-term health benefits justify the enormous financial investment.
For consumers, employers and investors alike, GLP-1 medications may be one of the most important healthcare-and-finance stories of the decade.
At Health to Wealth Ventures, we believe better health and better financial decisions go hand in hand. The future of healthcare isn’t just about what medicine can do… it’s about whether we can make those advances accessible, sustainable and financially responsible.
This article is for informational and educational purposes only and should not be considered medical, financial, investment or insurance advice.
References
Reuters. (2026, August 31). GLP-1 drugs are almost single-handedly forcing employers to reconsider workers’ health care.
Centers for Medicare & Medicaid Services. (2026, August 14). BALANCE: Better Approaches to Lifestyle and Nutrition for a Healthy America.
Reuters. (2026, August 31). Booming weight-loss drug demand in Brazil fuels thriving black market and health fears.
When investors hear VICI Properties Inc. (NYSE: VICI), the first thing that usually comes to mind is Las Vegas and for good reason. VICI owns the real estate behind some of the most recognizable gaming and entertainment properties in the country, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.
But describing VICI as simply a “casino REIT” undersells the company.
VICI is an experiential real-estate investment trust that owns 103 properties across the United States and Canada, including 63 gaming properties and 40 other experiential properties. Its portfolio encompasses approximately 130 million square feet, 66,000 hotel rooms and more than 700 restaurants, bars, nightclubs and sportsbooks.
The company’s business model is particularly attractive from a cash-flow perspective: VICI generally owns the real estate while experienced operators run the businesses. Those operators pay VICI rent through long-term triple-net leases, meaning the tenants generally assume responsibility for property-level expenses such as taxes, insurance and maintenance.
That structure gives VICI something investors should appreciate: relatively predictable recurring rental revenue without having to operate the casinos itself.
And at today’s share price, that cash-flow model is becoming increasingly interesting.
The Regent casino resort glows beside landscaped lagoons and the sea at dusk.
The Stock Is Trading at a Significant Discount to Its 52-Week High
VICI closed around $26.51 on August 21, 2026, leaving the stock roughly 22% below its 52-week high of $33.92.
That decline is important because VICI’s underlying business has not collapsed.
Quite the opposite.
In its most recent quarter, VICI reported:
Revenue: approximately $1.1 billion, up 5.7% year over year
AFFO: $679.6 million, up 7.8%
AFFO per share: $0.62, up 4.6%
Full-year 2026 AFFO guidance: $2.45–$2.47 per share
AFFO- adjusted funds from operations is arguably the more important metric for a REIT investor because it provides a better picture of the recurring cash-generating capacity of the business than conventional GAAP earnings.
That distinction matters with VICI.
The company’s second-quarter GAAP net income fell sharply year over year, but management attributed much of the decline to a change in its non-cash credit-loss allowance. AFFO, meanwhile, increased.
In other words, the headline EPS number looks considerably worse than the underlying recurring cash-flow picture.
The Dividend Is the Big Attraction
VICI currently pays a $0.45 quarterly dividend, or $1.80 annually if maintained at the current rate. The company has maintained the $0.45 quarterly payout through 2026.
At approximately $26.51 per share, that equates to a forward dividend yield of roughly:
$1.80 ÷ $26.51 = 6.79%
That’s a substantial yield for an S&P 500 company.
More importantly, VICI’s dividend has grown considerably since the company was formed. VICI’s annual dividend increased from $1.00 in 2018 to $1.77 in 2025, while the 2026 quarterly rate stands at $0.45.
Dividend Growth
Year
Annual Dividend
2018
$1.00
2019
$1.17
2020
$1.26
2021
$1.38
2022
$1.50
2023
$1.61
2024
$1.70
2025
$1.77
2026 annualized
$1.80
Source: VICI Properties investor relations.
The growth rate has moderated as VICI has become larger, but the direction remains favorable.
Is the Dividend Covered?
This is where VICI gets particularly interesting.
Management’s 2026 AFFO guidance is $2.45–$2.47 per share. At a $1.80 annual dividend, the implied AFFO payout ratio is approximately 73%.
Using the midpoint of guidance:
$1.80 ÷ $2.46 = 73.2%
That leaves approximately 27% of AFFO per share above the current dividend.
For a REIT, that is a much more meaningful coverage measure than comparing the dividend with GAAP EPS.
It doesn’t mean the dividend is risk-free. VICI carries substantial debt, and REITs are particularly sensitive to interest rates and credit-market conditions. But the current payout appears reasonably supported by recurring AFFO.
VICI’s Growth Story Is Expanding Beyond Traditional Gaming
One of the more interesting aspects of VICI’s strategy is that management is trying to reduce the company’s dependence on traditional casino real estate.
During the second quarter, VICI added several important relationships.
The company welcomed Clairvest as its 14th tenant, Golden Entertainment as its 15th, and Club Med as its 16th tenant.
The Golden Entertainment transaction is particularly notable. VICI’s new Golden Entertainment Master Lease carries approximately $87 million in initial annual rent, a 30-year initial term and 2% annual rent escalators beginning in lease year three.
VICI also acquired the Carambola Beach Resort in St. Croix and plans to fund approximately $55.2 million of redevelopment through a build-to-suit arrangement with Club Med. The targeted reopening is in the fourth quarter of 2027.
That’s an important strategic development.
VICI isn’t abandoning gaming. Gaming remains its core competency.
But the company is increasingly attempting to become the landlord behind experiential destinations, including hospitality, wellness, golf and entertainment.
That potentially gives VICI a larger addressable market over time.
The Balance Sheet Is the Part Investors Should Watch
The biggest counterargument to the bullish VICI thesis is leverage.
As of June 30, 2026, VICI had approximately $17.2 billion of total debt and approximately $2.5 billion of liquidity, including cash and availability under its revolving credit facility.
That is not insignificant.
A REIT with substantial debt can perform very well when interest rates cooperate, but higher rates increase the cost of refinancing and can reduce the relative attractiveness of REIT yields compared with bonds and other fixed-income investments.
The good news is that VICI has continued to demonstrate access to capital and has been using interest-rate swaps to manage some future interest-rate exposure. As of June 30, the company had entered into $600 million of forward-starting interest-rate swaps.
The bad news is simple:
VICI doesn’t need a business crisis to underperform. Higher-for-longer interest rates alone can pressure the valuation.
That is one reason the stock can offer a nearly 7% yield while still trading at a discount to its previous highs.
What About a Swing Trade?
This is where VICI gets especially interesting.
VICI isn’t typically thought of as a swing-trading stock. It is a relatively mature REIT designed more for income and total return.
But that doesn’t mean it can’t be traded.
At approximately $26.51, the stock is sitting substantially below its prior $33.92 high.
Wall Street’s valuation suggests the market may have become too pessimistic. Current analyst estimates vary, but several consensus sources place the average 12-month target around $31–$33, with some targets as high as $38.
That creates an interesting setup.
A Potential Swing-Trade Framework
Entry zone: approximately $25.75–$26.50
Initial target: approximately $28.50–$30.00
Secondary target: approximately $31–$32.50
Bull-case target: approximately $33–$34
Risk-management level: roughly $24.50–$25.00, depending on the trader’s risk tolerance and confirmation of a breakdown.
These aren’t guaranteed support and resistance levels; they’re a framework based on the stock’s recent trading range, prior price behavior and current valuation.
The key technical question is whether VICI can establish a sustained move above the $27–$28 area.
If it can, the next move toward $30 becomes considerably more interesting.
If the stock instead loses the mid-$25 area on heavy volume, the swing-trade thesis weakens and investors should be prepared for another leg lower.
The Dividend Creates an Interesting Trading Dynamic
There’s another reason VICI is different from many swing trades.
A trader buying VICI isn’t simply betting on price appreciation.
At the current annualized dividend, an investor receives approximately 6.8% annualized income while waiting for the market to recognize the potential valuation opportunity.
For example, a hypothetical $10,000 investment at $26.51 would purchase approximately 377 shares.
At $1.80 per share annually, those shares would generate approximately:
$679 per year in dividends
before taxes, assuming the dividend remains unchanged.
If VICI subsequently rose from $26.51 to $30:
Capital gain: approximately $1,316
Annual dividend income: approximately $679
Potential combined one-year return: approximately $1,995, or roughly 20%
That’s not a forecast. It’s simply an illustration of why a high-yield REIT can offer an attractive total-return setup when bought at a depressed valuation.
The Risks Should Not Be Ignored
The bullish case is compelling, but VICI isn’t a risk-free 7% yield.
1. Interest-rate risk
REIT valuations can suffer when Treasury yields rise because investors demand a higher yield from real estate securities.
2. Leverage
Approximately $17.2 billion of debt means refinancing costs and credit-market conditions matter.
3. Tenant concentration
Although VICI is diversifying its tenant base, gaming remains central to the portfolio. The financial health of major operators remains important to VICI’s rent collection.
4. Gaming-cycle risk
Casino and entertainment spending is discretionary. A recession or deterioration in consumer spending could negatively affect tenants.
5. Regulatory risk
Gaming is heavily regulated. VICI’s tenants must maintain the necessary licenses and regulatory approvals to operate their properties.
6. Dividend-growth moderation
The dividend is attractive, but investors shouldn’t assume the double-digit dividend-growth rates VICI achieved earlier in its history will continue indefinitely.
VICI itself highlights interest rates, tenant credit risk, gaming-industry conditions, regulation, leverage and economic conditions among the factors that could materially affect future results.
My Take: VICI Looks More Interesting at $26.50 Than It Did at $34
At approximately $26.51, VICI presents an unusual combination:
A high-quality experiential real estate portfolio + long-term leases + growing AFFO + a nearly 7% dividend yield + a stock price more than 20% below its 52-week high.
The market is clearly demanding a risk premium.
And investors should understand why.
The company has significant debt, remains exposed to interest rates and still derives substantial economics from the gaming industry.
But the latest operating numbers don’t suggest a deteriorating business.
Second-quarter AFFO per share increased 4.6%, management raised the low end of its 2026 AFFO guidance, and the company continues to expand its tenant base and experiential real-estate footprint.
At $26.51, VICI trades at roughly 10.8 times the midpoint of management’s 2026 AFFO guidance.
That’s a valuation I find considerably more compelling than the stock’s previous $33–$34 range.
Bottom Line
For income investors: VICI’s approximately 6.8% yield and roughly 73% AFFO payout ratio make the stock worth serious consideration for a diversified income portfolio.
For value investors: The stock’s discount from its 52-week high combined with growing AFFO creates an attractive risk/reward profile if interest-rate pressures ease.
For swing traders: The $25.75–$26.50 area offers an intriguing entry zone, with $28.50–$30 representing a reasonable first profit-taking region and $31–$33 providing a larger upside target if momentum improves.
My overall view:VICI is more attractive as a buy-and-hold income/total-return position than as a pure short-term trade but the current valuation creates a legitimate swing-trade opportunity as well.
The most important catalyst to watch isn’t simply the next dividend.
It’s whether AFFO continues growing while interest-rate pressure on REIT valuations begins to fade.
If those two variables move in VICI’s favor, today’s $26–$27 price could eventually look like an attractive entry point in hindsight.
Investor Disclosure
Disclosure: I own a position in VICI Properties (VICI). This article reflects my personal analysis and is intended for informational and educational purposes only. It is not a recommendation to buy, sell or hold VICI or any other security. I may have a financial interest in the outcome of the analysis. Investors should conduct their own due diligence and consider their individual financial objectives, risk tolerance and investment horizon before making investment decisions.
References
MarketBeat. (2026, July 29). VICI Properties Inc. issues FY 2026 earnings guidance. MarketBeat source
MarketScreener. (2026). VICI Properties, Inc.: Target price consensus and analysts recommendations. MarketScreener consensus data
U.S. Securities and Exchange Commission. (2026). VICI Properties Inc. and VICI Properties L.P. annual report on Form 10-K for the year ended December 31, 2025. SEC filing
VICI Properties Inc. (2026, February 25). VICI Properties Inc. announces fourth quarter and full year 2025 results. VICI Properties investor relations
At Health to Wealth Ventures, I’ve always believed that true wealth begins with good health. That’s why I’ve made the decision to openly document my experience with Transcranial Magnetic Stimulation (TMS) as I work toward recovery from depression and reclaiming the best version of myself.
A hiker walks along a rocky mountain trail at sunrise with a stunning mountain range ahead.
This week marked the completion of another week of treatment.
The journey hasn’t been easy, but it has been worthwhile. Like many people beginning TMS, I’ve experienced moments of hope, fatigue, mental fog, and emotional ups and downs. While I’m still early in the process and not expecting overnight results, I’ve already noticed small signs that encourage me to keep moving forward.
One lesson this experience has reinforced is that recovery is rarely linear. Healing takes patience, consistency, and the willingness to trust the process even on the difficult days.
Outside of treatment, I’ve remained committed to healthy habits that support both my physical and mental well-being. Daily walks, exercise, preparing healthy meals, maintaining routines, and leaning on family and friends have all become important pieces of my recovery. TMS is one tool, but lasting wellness comes from caring for the whole person.
By sharing this journey, my hope is that others battling depression realize they are not alone. Mental health deserves the same attention and compassion as physical health, and seeking treatment is a sign of strength not weakness.
A glowing, ethereal river winds through lush green hills under a twilight sky.
As Dwayne “The Rock” Johnson once said, “Depression never discriminates.” Those simple words remind us that mental illness can affect anyone, regardless of success, background, or circumstance.
I’m optimistic about the weeks ahead and committed to seeing this treatment through. Once I complete my full course of TMS, I’ll publish a comprehensive update sharing my experience, what I’ve learned, and whether the treatment helped me achieve the recovery I’ve been working toward.
Thank you for following along and for your continued encouragement. If sharing my story helps even one person take the first step toward getting help, then this journey will have an impact far beyond my own recovery.
Remember: Your health is your greatest investment, and investing in your mental health is one of the most valuable decisions you can make.
Rocket Lab Corporation (NASDAQ: RKLB) has grown from a niche small-satellite launch company into one of the world’s leading publicly traded space technology companies. Founded in 2006 by aerospace engineer Peter Beck, the company has successfully diversified beyond rocket launches by manufacturing satellites, spacecraft components, and providing end-to-end space systems for commercial, civil, and defense customers. Its Electron rocket has become one of the most frequently launched small orbital launch vehicles, while its next-generation Neutron rocket is expected to significantly expand the company’s capabilities in the medium-lift launch market.
Rocket Lab shares closed at $67.62 on Friday, July 17, 2026, recovering slightly after a volatile week that saw the stock decline more than 11% on July 16. Despite the recent correction, the company remains one of the fastest-growing names in the commercial space industry, with investors closely watching several major catalysts that could influence its long-term trajectory.
Reasons for Long-Term Upside
Neutron Rocket Development
The single largest catalyst for Rocket Lab is the development of its reusable Neutron launch vehicle. Designed to compete for larger commercial, government, and national security missions, Neutron has the potential to dramatically increase Rocket Lab’s revenue opportunities while improving launch economics. Successful execution could transform Rocket Lab from a niche launch provider into a direct competitor within the medium-lift launch market.
Diversified Revenue Streams
Unlike many emerging space companies, Rocket Lab has built a diversified business model. Through its Space Systems division, the company generates revenue from satellite manufacturing, spacecraft components, solar power systems, reaction wheels, flight software, and mission operations. This diversification reduces dependence on launch revenue alone and provides more stable long-term growth.
Growing Government Business
Rocket Lab continues to strengthen relationships with NASA, the U.S. Department of Defense, and the U.S. Space Force. On July 17, the company was among several launch providers included in an expanded $17 billion National Security Space Launch Phase 3 contract ceiling, reinforcing its position as an important supplier for future government launch opportunities. While future task orders are not guaranteed, inclusion demonstrates continued confidence in Rocket Lab’s capabilities.
Expanding Commercial Space Economy
Demand for satellite deployment continues to accelerate as communications, Earth observation, defense, and scientific missions expand globally. Rocket Lab is well positioned to benefit from this long-term secular trend thanks to its vertically integrated business model.
Risks Investors Should Consider
A satellite releases numerous small CubeSats into Earth’s orbit against a starry backdrop.
Execution Risk
Rocket Lab’s valuation assumes continued execution across multiple high-profile projects. Delays in Neutron development, unexpected engineering challenges, or launch failures could negatively affect both financial performance and investor sentiment.
Intense Competition
Rocket Lab competes against well-funded companies including SpaceX, Blue Origin, Firefly Aerospace, Relativity Space, and several emerging international launch providers. Maintaining technological leadership while preserving margins will remain a significant challenge.
Premium Valuation
Although the recent selloff has reduced some of the market’s enthusiasm, Rocket Lab still trades at a valuation that reflects considerable future growth expectations. Investors are paying for tomorrow’s potential earnings rather than today’s profitability, making the stock particularly sensitive to execution disappointments.
Market Volatility
Rocket Lab remains a high-beta growth stock. The shares have experienced substantial price swings throughout 2026 as investors rotate between growth sectors and reassess valuations across the aerospace industry. Investors should be prepared for continued volatility despite the company’s favorable long-term outlook.
Investment Outlook
Rocket Lab remains one of the most compelling growth stories in the commercial space sector. The combination of a growing launch business, expanding Space Systems division, increasing government partnerships, and the anticipated debut of Neutron provides multiple avenues for future growth.
However, investors should recognize that Rocket Lab is still an execution-driven investment. While the long-term opportunity appears significant, meaningful risks remain, particularly surrounding product development timelines, competition, and market valuation.
For investors with a long-term investment horizon and a tolerance for volatility, Rocket Lab may represent an attractive opportunity to participate in the continued expansion of the global space economy.
Disclosure
Disclosure: I currently hold a long position in Rocket Lab Corporation (NASDAQ: RKLB). The opinions expressed in this article are solely my own and are intended for informational and educational purposes only. This article does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a licensed financial professional before making any investment decisions.
Mental health is often a topic that families struggle to talk about. We may know about physical illnesses that run in our families heart disease, diabetes, cancer but we don’t always discuss depression, anxiety, trauma, or other mental health challenges with the same openness.
Recently, I found myself reflecting on my father’s story and how family experiences can shape the way we understand mental health.
A large tree with roots naturally forming a heart shape in a sunlit forest
My father suffered a heart attack at a relatively young age. He was a heavy smoker, and his heart health was something that impacted our family. After that heart attack, he told me he had taken lithium, explaining that it was for his heart. Looking back, I now understand that lithium is not typically used as a heart medication. It is most commonly associated with mood stabilization, particularly for conditions such as bipolar disorder and certain forms of treatment-resistant depression.
The truth is, I may never know exactly why he took it. Medical records are not always available, and sometimes family members remember medications or diagnoses differently than they were documented. But the conversation made me think about something deeper: the connection between trauma, mental health, and family history.
My father experienced a devastating loss when his brother was shot and killed by his wife. They were extremely close, and a tragedy like that can leave a lasting emotional impact. Severe trauma and grief can contribute to depression, anxiety, PTSD, and other mental health struggles. While we cannot assume exactly what my father experienced or what treatment he needed, it reminds me that emotional wounds can be just as real as physical ones.
That realization has also caused me to reflect on my own mental health journey.
I have been working through depression and other challenges, and I am now beginning a new chapter by starting Transcranial Magnetic Stimulation (TMS) therapy. TMS is a noninvasive treatment that uses magnetic pulses to stimulate specific areas of the brain involved in mood regulation. For many people who have not found enough relief through medication alone, TMS can provide another option.
Starting TMS is not about giving up on previous treatments it is about continuing to search for what works. Mental health treatment is often a process of finding the right combination of therapies, medications, lifestyle changes, support systems, and self-awareness.
A glowing brain surrounded by radiant light beams breaking through darkness
As I begin this journey, I want to share a few lessons I have learned:
1. Family history matters. Understanding the experiences, struggles, and challenges within our families can provide important context for our own health journeys.
2. Trauma can affect generations. Painful events do not always end when the event is over. Grief, loss, and trauma can influence how people cope, communicate, and seek help.
3. Mental health deserves the same attention as physical health. We would never tell someone with heart disease to simply “push through it.” Depression and other mental health conditions deserve compassion, treatment, and support.
4. Healing is not always a straight line. Sometimes progress comes from trying something new, adjusting course, and being willing to ask for help.
At Health to Wealth Ventures, the goal has always been to look at the complete picture of health, mind, body, finances, safety, and quality of life. True wealth is not just measured by what we own; it is also measured by our ability to enjoy life, maintain relationships, and take care of ourselves.
My TMS journey is just beginning. I don’t know exactly what the outcome will be, but I do know this: seeking help is a sign of strength, not weakness.
By sharing our stories, we can help remove the stigma around mental health and remind others that they are not alone in their journey toward healing.
Health is the foundation. Wealth is the opportunity. Together, they create a life worth living.
Auto insurance policies are not always kept for their full term. Whether a policyholder sells a vehicle, finds a better rate, moves to another state, or simply decides to switch carriers, insurance policies are often canceled before their expiration date.
What many consumers don’t realize is that not all cancellations are calculated the same way. Depending on who initiates the cancellation and when it occurs, the refund amount may vary significantly.
The three most common types of auto insurance cancellations are Pro-Rata, Short-Rate, and Flat Cancellations.
A car insurance policy, calculator, cash, and keys on a wooden desk
What Is a Pro-Rata Cancellation?
A pro-rata cancellation occurs when the insurance company cancels the policy or when a cancellation is processed without any penalty.
Under a pro-rata cancellation, the policyholder receives a refund for all unused premium on a straight-line basis.
Example
Assume:
Annual premium: $1,200
Policy term: 12 months
Policy canceled after 3 months
The policyholder used 25% of the coverage period and is entitled to a refund of the remaining 75%.
Premium paid: $1,200
Earned premium: $300
Refund: $900
No cancellation fee is deducted.
Common Reasons for Pro-Rata Cancellations
Insurance company non-renews or cancels coverage
Vehicle is totaled and coverage ends
State regulatory requirements mandate a full refund calculation
Certain carrier-specific cancellation provisions
What Is a Short-Rate Cancellation?
A short-rate cancellation is the most common form of cancellation when the policyholder voluntarily cancels coverage before the policy expires.
With a short-rate cancellation, the insurer retains slightly more premium than the exact amount earned. This creates a financial penalty intended to offset administrative costs associated with issuing and canceling the policy.
Example
Assume:
Annual premium: $1,200
Policy canceled after 3 months
Unearned premium: $900
Instead of receiving the full $900 refund, the carrier applies a short-rate penalty.
Potential refund:
Unearned premium: $900
Short-rate penalty: $45
Refund issued: $855
The exact penalty varies by carrier and state regulations.
Typical Short-Rate Fees
Many carriers use:
5% of the unearned premium
10% of the unearned premium
A fixed cancellation fee ranging from $25 to $75
A state-approved short-rate table
Why Insurers Use Short-Rate Cancellations
Insurance companies incur expenses when policies are issued, including:
Underwriting costs
Policy processing
Commission payments
Administrative expenses
Short-rate penalties help recover a portion of those costs when a customer leaves before the policy term ends.
What Is a Flat Cancellation?
A flat cancellation treats the policy as though it never existed.
The insurer returns 100% of the premium paid and no coverage is considered to have been in force.
Example
Assume:
Annual premium: $1,200
Policy purchased today
Customer discovers duplicate coverage and cancels before the policy effective date
Refund:
Premium paid: $1,200
Refund issued: $1,200
No premium is earned by the insurer.
Common Reasons for Flat Cancellations
Policy canceled before the effective date
Coverage obtained in error
Duplicate policies discovered
Underwriting declines coverage before policy inception
No claims or coverage exposure occurred
Comparing the Three Types of Cancellations
Cancellation Type
Refund Method
Penalty Applied?
Typical Situation
Flat Cancellation
100% refund
No
Policy never takes effect
Pro-Rata
Refund of unused premium
No
Insurer initiates cancellation
Short-Rate
Refund of unused premium minus fee
Yes
Customer voluntarily cancels
How Much Could Cancellation Fees Cost?
Consider a policy with a remaining unearned premium of $600:
Method
Refund
Flat Cancellation
$600
Pro-Rata Cancellation
$600
Short-Rate (5% Penalty)
$570
Short-Rate (10% Penalty)
$540
Short-Rate + $50 Fee
$550
While the difference may seem small, policyholders with higher premiums can lose hundreds of dollars when a short-rate penalty applies.
What Consumers Should Do Before Canceling
Before switching auto insurance companies:
Verify the effective date of your new policy.
Ask your current carrier whether a short-rate penalty applies.
Request the exact refund amount in writing.
Confirm there are no cancellation fees.
Avoid any lapse in coverage that could increase future insurance premiums.
Many consumers focus solely on the new premium savings and overlook cancellation penalties that can reduce the benefit of switching carriers.
A silver car under a transparent garage model on an October 2023 calendar.
The Takeaway Here
Understanding the difference between flat, pro-rata, and short-rate cancellations can help consumers make more informed decisions when changing auto insurance coverage. While flat and pro-rata cancellations generally provide the greatest refund, short-rate cancellations may reduce the amount returned through penalties or administrative fees.
Before canceling any auto policy, ask your insurance company or agent how the refund will be calculated. A simple phone call could prevent an unexpected deduction and help ensure a smooth transition to your new coverage.
Disclosure: This article is intended for educational purposes only. Cancellation rules, refund calculations, and fees vary by insurance carrier and state regulations. Consumers should consult their insurance policy and carrier for specific cancellation provisions.
About the Author:
David Dandaneau is a client relations analyst that covers the insurance and financial services industry. He is known for his insightful analysis and comprehensive coverage of market trends and regulatory developments.
Health to Wealth Ventures 